Suzhou Kangju Biotechnology

Suzhou Kangju Biotechnology is a clinical-stage biopharmaceutical company based in Suzhou, China, specializing in the discovery and development of innovative small molecule drugs targeting the ubiquitin-proteasome system (UPS). The company's primary focus is on oncology, with a lead candidate, KJ01, which is a potent and selective USP7 inhibitor currently in Phase 1 clinical trials for advanced solid tumors. Kangju Biotech leverages its proprietary platform to develop a pipeline of inhibitors targeting various deubiquitinating enzymes (DUBs) to address unmet medical needs in cancer and other serious diseases. The company is headquartered in the Suzhou Industrial Park and is supported by prominent venture capital investors. Its research efforts aim to provide first-in-class therapeutic options for patients with limited treatment alternatives.